This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Exact Sciences Stock (NASDAQ:EXAS) Get Exact Sciences alerts:Sign Up Key Stats Today's Range$104.91▼$104.9150-Day Range$102.25▼$104.9152-Week Range$38.81▼$104.98VolumeN/AAverage Volume3.55 million shsMarket Capitalization$20.03 billionP/E RatioN/ADividend YieldN/APrice Target$92.13Consensus RatingReduce Company Overview Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults. Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development. In 2019, the company completed the acquisition of Genomic Health, bringing Oncotype DX® diagnostic tests into its offerings. These tests assess gene expression profiles in breast, prostate and other cancers to help guide treatment decisions, furthering Exact’s mission to advance precision oncology. Exact Sciences sells its products primarily in the United States and has extended its reach into selected international markets, including Europe and Australia. The company operates a network of laboratories and works closely with healthcare providers, payers and policy makers to support the adoption of its screening and diagnostic technologies. Exact Sciences also invests in clinical trials and real-world evidence studies to validate and refine its assays. Kevin Conroy, who joined Exact Sciences in 2015 and became president and chief executive officer in 2017, leads the company’s efforts to integrate molecular diagnostics into standard cancer care. Under his leadership, Exact has grown its commercial infrastructure and doubled down on research initiatives aimed at developing next-generation tests for multiple tumor types. The company remains focused on improving patient outcomes through earlier detection and more personalized treatment pathways.AI Generated. May Contain Errors. Read More Exact Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreEXAS MarketRank™: Exact Sciences scored higher than 5% of companies evaluated by MarketBeat, and ranked 850th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingExact Sciences has received a consensus rating of Reduce. The company's average rating score is 1.95, and is based on no strong buy ratings, no buy ratings, 21 hold ratings, and 1 sell rating.Downside RiskExact Sciences has a consensus price target of $92.13, representing about 12.2% downside from its current price of $104.91.Amount of Analyst CoverageExact Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Exact Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($0.58) to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -95.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -95.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioExact Sciences has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 8.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for EXAS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for EXAS on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders1.20% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXAS Stock News HeadlinesAbbott Labs shares fall as earnings beat offset by Exact Sciences acquisition dragApril 16, 2026 | proactiveinvestors.comExact Sciences CorporationMarch 26, 2026 | edition.cnn.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO… | Paradigm Press (Ad)Abbott completes acquisition of Exact SciencesMarch 23, 2026 | finance.yahoo.comHow Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment StoryMarch 22, 2026 | finance.yahoo.com1 Mid-Cap Stock to Consider Right Now and 2 Facing HeadwindsMarch 17, 2026 | finance.yahoo.comExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026 | finance.yahoo.comExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026 | businesswire.comSee More Headlines EXAS Stock Analysis - Frequently Asked Questions How were Exact Sciences' earnings last quarter? Exact Sciences Corporation (NASDAQ:EXAS) posted its quarterly earnings data on Monday, November, 3rd. The medical research company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.13 by $0.11. Exact Sciences's quarterly revenue was up 20.0% on a year-over-year basis. Read the conference call transcript. Does Exact Sciences have any subsidiaries? Exact Sciences subsidiaries include Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and others. Who are Exact Sciences' major shareholders? Top institutional investors of Exact Sciences include Segall Bryant & Hamill LLC (0.01%). Insiders that own company stock include Kevin T Conroy, Katherine S Zanotti, Sarah Condella, James Edward Doyle, Everett Cunningham, D Scott Coward, Jacob A Orville, Daniel J Levangie, Brian Baranick, Jeffrey Thomas Elliott and James Herriott. View institutional ownership trends. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings11/03/2025Today5/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EXAS's financial health is in the Green zone, according to TradeSmith. EXAS has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees7,200Year Founded1995Price Target and Rating Average Price Target for Exact Sciences$92.13 High Price Target$105.00 Low Price Target$46.00 Potential Upside/Downside-12.2%Consensus RatingReduce Rating Score (0-4)1.95 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth2.02Net Income-$207.95 million Net Margins-6.40% Pretax Margin-6.28% Return on Equity0.53% Return on Assets0.22% Debt Debt-to-Equity Ratio0.97 Current Ratio2.43 Quick Ratio2.17 Sales & Book Value Annual Sales$3.25 billion Price / Sales6.17 Cash Flow$1.27 per share Price / Cash Flow82.83 Book Value$12.58 per share Price / Book8.34Miscellaneous Outstanding Shares190,888,000Free Float188,597,000Market Cap$20.03 billion OptionableOptionable Beta1.41 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:EXAS) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
